content top

Musculoskeletal Imaging in the Era of Molecular Medicine.

Time:

2:00 PM- 3:30 PM

Author:

Homer Aquino Macapinlac, Philipp Mayer-Kuckuk, and Sandip Biswal

Code: RC117

Objective:

This session includes three sections; the first one is Clinical Radionuclide Imaging Agents for Musculoskeletal Malignancies, which reviews the clinical utility of Tc-99m MDP planar and SPECT/CT imaging as well as F18 Fluoride /CT in patients with Musculoskeletal Malignancies. This section will also review the clinical utility of FDG PET/CT for staging and assessing response to staging in patients with Musculoskeletal Malignancies. The section will discuss the preliminary clinical imaging studies utilizing novel PET tracers for assessing early response to therapy, treatment planning and prognosis. The second section, in Orthopedic Research, is highlighting the definition of molecular imaging and the rational for the application of molecular imaging to the musculoskeletal system. Attendees will learn how to confer imaging visibility to a biological target (probes & reporter genes). Attendees will also learn the principles, advantages, and limitations of optical (bioluminescence and fluorescence) imaging in preclinical animal models. The section will highlight examples of preclinical applications of optical imaging for the study of musculoskeletal function, disease, and gene/cell therapy. It will discuss the future clinical translation of musculoskeletal molecular imaging: Assessment of feasibility and new ideas. The third section is New Developments in Imaging for Musculoskeletal Pain, which reviews the limitations of current imaging approaches in the assessment of chronic pain generators. The section will also review, in brief, pain neurobiology and physiology and demonstrate how these can be exploited as targets for new approaches towards ‘imaging pain’. This section will review novel MR Imaging and PET methods being used to identify chronic pain generators in the peripheral and central nervous system.

Share


Leave a Reply

*